ProQR spins out rare disease play Amylon

ProQR Therapeutics N.V. (NASDAQ:PRQR) spun out CNS-focused Amylon Therapeutics B.V. (Leiden, the Netherlands), which simultaneously raised an undisclosed amount in a seed funding from private and institutional investors. ProQR granted Amylon an exclusive license to develop therapeutics for beta amyloid related disorders.

ProQR retains a majority stake in Amylon and is eligible for milestones and royalties...